Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
GAITHERSBURG, Md. , May 10, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format...
Emergent BioSolutions Reports First Quarter 2024 Financial Results
First Quarter 2024 Total Revenues of $300.4 million , above the prior guidance range First Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 million Updates FY 2024 guidance...
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficiently Reorganization will align with evolving...
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an...
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
GAITHERSBURG, Md. , April 30, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing...
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GAITHERSBURG, Md. , April 22, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN ® Nasal Spray and build on its...
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GAITHERSBURG, Md. , March 25, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or...
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Fourth Quarter 2023 Total Revenues of $277 million , which aligned our Full Year to the mid-point of guidance Full Year 2023 Total Revenues of $1 .05 billion, which was the mid-point of guidance...
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md. , Feb. 21, 2024 (GLOBE NEWSWIRE) —...
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
GAITHERSBURG, Md. , Jan. 11, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement...